The estimated Net Worth of Richard A Mark is at least $1.42 Milhão dollars as of 3 March 2024. Mr. Mark owns over 18,855 units of Mylan NV stock worth over $1,146,478 and over the last 5 years he sold MYL stock worth over $0. In addition, he makes $277,506 as Non-Executive Independent Director at Mylan NV.
Richard has made over 7 trades of the Mylan NV stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 18,855 units of MYL stock worth $298,852 on 3 March 2024.
The largest trade he's ever made was exercising 20,313 units of Mylan NV stock on 3 March 2023 worth over $321,961. On average, Richard trades about 5,437 units every 120 days since 2019. As of 3 March 2024 he still owns at least 72,333 units of Mylan NV stock.
You can see the complete history of Mr. Mark stock trades at the bottom of the page.
Richard Mark CPA serves as Non-Executive Independent Director of the Company. Mr. Mark currently serves on the board of directors of Goldman Sachs Middle Market Lending Corp., chairing its Audit Committee as an audit committee financial expert and serving on its Compliance, Governance and Nominating, and Contract Review committees. He previously served as a partner with Deloitte from June 2002 to May 2015, most recently leading the advisory corporate development function. Prior to joining Deloitte, Mr. Mark held various positions with Arthur Andersen & Co., including audit partner. Mr. Mark also served from July 2015 until August 2016 as Chairman of the Board of Directors and as a member of the Audit Committee of Katy Industries, Inc., a manufacturer, importer and distributor of commercial cleaning and consumer storage products. He also served on the board of directors of Cadence Health from 1993 until its acquisition by Northwestern Memorial Healthcare (“Northwestern”) in September 2014. Following the acquisition of Cadence Health, Mr. Mark was a director of Northwestern from September 2014 to August 2015, serving on its Executive and Nominating and Governance committees. Mr. Mark currently serves as a director of Almost Home Kids, a not-for-profit corporation affiliated with Lurie Children’s Hospital of Chicago, which provides transitional care to children with complicated health needs, training for their families, and respite care. As previously disclosed, Mr. Mark will serve as a director of Viatris upon the closing of the Combination. Mr. Mark’s qualifications to serve on Mylan’s Board include, among others, his experience and expertise regarding finance, the healthcare industry, global business, corporate governance, public company management, risk oversight and strategy, and international M&A.
As the Non-Executive Independent Director of Mylan NV, the total compensation of Richard Mark at Mylan NV is $277,506. There are 12 executives at Mylan NV getting paid more, with Heather Bresch having the highest compensation of $18,509,300.
Richard Mark is 67, he's been the Non-Executive Independent Director of Mylan NV since 2019. There are 3 older and 9 younger executives at Mylan NV. The oldest executive at Mylan NV is Robert Cindrich, 76, who is the Non-Executive Independent Director.
Richard's mailing address filed with the SEC is 1000 MYLAN BOULEVARD, , CANONSBURG, PA, 15317.
Over the last 10 years, insiders at Mylan NV have traded over $1,861,785,794 worth of Mylan NV stock and bought 202,008 units worth $5,767,632 . The most active insiders traders include Laboratories Abbott Product..., Daniel Martin Jr Gallagher, eRobert J Coury. On average, Mylan NV executives and independent directors trade stock every 15 days with the average trade being worth of $5,605,891. The most recent stock trade was executed by Robert J Cindrich on 16 November 2020, trading 9,440 units of MYL stock currently worth $149,624.
Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.
Mylan NV executives and other stock owners filed with the SEC include: